Quote:I find this far from transparent and worse…deeply troubling if true:
New Zealand Fudged The Data On How Kidneys Fare After COVID Vaccines
https://www.zerohedge.com/medical/new-zealand...d-vaccines
Tyler Durden and Zero Hedge? Why would you seriously consider a site who boosts conspiracy theories for views to be an adequate source of information.
What "Tyler" conveniently didn't mention in the article is this -
Quote:The SIRs for 11 of the 12 selected AESIs were not statistically significantly increased post vaccination... A statistically significant association between BNT162b2 vaccination and myo/pericarditis was observed. This association has been confirmed internationally. BNT162b2 was not found to be associated with the other AESIs investigated, except for SOCV following the first dose of BNT162b2 in the 20–39 years age group only, providing reassurances around the safety of the vaccine.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442303/
Why the rise in myo/pericarditis? Very simple, vaccines are an antigen meant to produce an immune response to a specific virus. What do you get with a rapid rise in immune response, inflammation.
If you think it's only applicable to mRNA vaccines think again.
Quote:Data from the clinical trials of the Novavax COVID-19 vaccine and post-authorization vaccine safety monitoring outside the United States suggest an increased risk of myocarditis and pericarditis following Novavax vaccination.
Ihttps://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html#:~:text=Data%20from%20the%20clinical%20trials,and%20pericarditis%20following%20Novavax%20vaccination
Quote:Montelukast sales roared along even after reports of neuro-psychiatric side effects
With the black box warning physicians should be prescribing it only in the most severe cases but one has to wonder if the pharma company is providing doctors with legal kickbacks.
Took a look at what Montelukast does - Montelukast causes inhibition of airway cysteinyl leukotriene receptors. The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 on target cells to contract bronchial and vascular smooth muscle, to increase permeability of small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit leukocytes to sites of inflammation.
Leronlimab does all that Montekulast does and is neuroprotective.
19
